Copertina

Preface to the Review Series Neuropharmacology of addiction

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Andrew J. Lawrence, Christopher J. Langmead
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	British Journal of Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Mindfulness‐Oriented Recovery Enhancement: Implementing an evidence‐based intervention for chronic pain, opioid use, and opioid addiction in clinical settings
di: Eric L. Garland
Pubblicazione: (2024)

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
di: Fleur Veldman, et al.
Pubblicazione: (2026)

Non‐canonical nitric oxide signalling and DNA methylation: Inflammation induced epigenetic alterations and potential drug targets
di: Christopher H. Switzer
Pubblicazione: (2024)

Gβγ subunit activation of K V 7 and BK Ca channels underlies calcitonin gene‐related peptide vasorelaxation in myogenic rat coronary resistance arteries
di: Lucy A. Donovan, et al.
Pubblicazione: (2026)

Neuroprotective amyloid β N‐terminal peptides differentially alter human α7‐ and α7β2‐nicotinic acetylcholine (nACh) receptor single‐channel properties
di: Catherine F. Roberts, et al.
Pubblicazione: (2024)

Justifying and reporting the use of severe stress in experiments that use animals
di: S. Clare Stanford, et al.
Pubblicazione: (2026)

The opioid partial agonist PPL‐138 reduces alcohol self‐administration in rats susceptible to post‐traumatic stress disorder
di: Andrea Cippitelli, et al.
Pubblicazione: (2025)

Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms
di: Ryan J. Rakoczy, et al.
Pubblicazione: (2024)

Advancing the field of viroporins—Structure, function and pharmacology: IUPHAR Review 39
di: Kira Devantier, et al.
Pubblicazione: (2024)

Pharmacological inhibition of STING reduces neuroinflammation‐mediated damage post‐traumatic brain injury
di: Amelia L. Fryer, et al.
Pubblicazione: (2024)

Characterisation of neurogenic lipolytic responses in white adipose tissue ex vivo
di: Kayleigh E. Goddard, et al.
Pubblicazione: (2025)

Only time will tell: Modelling the kinetics of covalent inhibitors
di: Madeeha I. Ali, et al.
Pubblicazione: (2026)

Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC1 receptor
di: Zoe Tasma, et al.
Pubblicazione: (2024)

Emerging therapeutic opportunities for psychedelic and related drugs
di: Susan Wonnacott, et al.
Pubblicazione: (2026)

Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation
di: Aida Mohammadkhani, et al.
Pubblicazione: (2024)

Pharmacological profiling of small molecule modulators of the TMEM16A channel and their implications for the control of artery and capillary function
di: Rumaitha Al‐Hosni, et al.
Pubblicazione: (2025)

Highlights and hot topics in GPCR research from ‘Down Under’
di: Nicola J. Smith, et al.
Pubblicazione: (2024)

Postnatal hypofunction of N‐methyl‐D‐aspartate receptors alters perforant path synaptic plasticity and filtering and impairs dentate gyrus‐mediated spatial discrimination
di: Luis A. Márquez, et al.
Pubblicazione: (2024)

Psilocybin as a novel treatment for chronic pain
di: Tate Askey, et al.
Pubblicazione: (2024)

C‐model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement system
di: Lucía Alfonso‐González, et al.
Pubblicazione: (2025)

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
di: Stephen P. H. Alexander, et al.
Pubblicazione: (2025)

The mitochondrial calcium uniporter inhibitor Ru265 increases neuronal excitability and reduces neurotransmission via off‐target effects
di: Peng Xu, et al.
Pubblicazione: (2024)

The Australia story: Current status and future challenges for the clinical applications of psychedelics
di: David J Nutt, et al.
Pubblicazione: (2024)

Role of inflammasomes in endothelial dysfunction
di: Jimin Wu, et al.
Pubblicazione: (2024)

Chronic Δ9‐tetrahydrocannabinol exposure during adolescence is associated with persistent behavioural tolerance in adult nonhuman primates
di: Yasaman Razavi, et al.
Pubblicazione: (2025)

Activation of M4 muscarinic receptors in the striatum reduces tic‐like behaviours in two distinct murine models of Tourette syndrome
di: Roberto Cadeddu, et al.
Pubblicazione: (2024)

The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial
di: Hongtao Yu, et al.
Pubblicazione: (2024)

Biased agonists of GPR84 and insights into biological control
di: Vincent B. Luscombe, et al.
Pubblicazione: (2024)

SCA44‐ and SCAR13‐associated GRM1 mutations affect metabotropic glutamate receptor 1 function through distinct mechanisms
di: Yuyang Wang, et al.
Pubblicazione: (2024)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
di: Laith Alexander, et al.
Pubblicazione: (2024)

Structure–activity relationship of the allosteric effects of ivermectin at human P2X4 and GABAA receptors
di: Jessica L. Meades, et al.
Pubblicazione: (2025)

Neurokinin‐1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice
di: Alexander Widiapradja, et al.
Pubblicazione: (2026)

Targeting the tyrosine kinase Src in endothelium attenuates inflammation and atherogenesis induced by disturbed flow
di: Huanyu Ding, et al.
Pubblicazione: (2024)

Cannabigerol reverses mechanical allodynia through α 2A ‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy
di: Quinn W. Wade, et al.
Pubblicazione: (2025)

Sex differences in the vasoactive effect of transient receptor potential channels: TRPM3 as a new therapeutic target for (neuro)vascular disorders
di: Eduardo Rivera‐Mancilla, et al.
Pubblicazione: (2025)

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors
di: Stephen P. H. Alexander, et al.
Pubblicazione: (2025)

Ligand bias and inverse agonism on 5‐HT2A receptor‐mediated modulation of G protein activity in post‐mortem human brain
di: Itziar Muneta‐Arrate, et al.
Pubblicazione: (2024)

Inactivation induced by pathogenic Cav1.3 L‐type Ca2+‐channel variants enhances sensitivity for dihydropyridine Ca2+ channel blockers
di: Ferenc Török, et al.
Pubblicazione: (2024)

The potential of an Innovative Licensing and Access Pathway metapolicy on the United Kingdom's life sciences strategy
di: James Andrew Levine
Pubblicazione: (2025)

Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction
di: Jake E. Doiron, et al.
Pubblicazione: (2024)